IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.771
NA - Nord America 640
EU - Europa 311
SA - Sud America 91
AF - Africa 18
OC - Oceania 11
Totale 4.842
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.942
US - Stati Uniti d'America 600
CN - Cina 433
HK - Hong Kong 296
GB - Regno Unito 88
BR - Brasile 71
DE - Germania 65
IT - Italia 39
CZ - Repubblica Ceca 34
VN - Vietnam 31
CA - Canada 19
IN - India 19
FI - Finlandia 16
NL - Olanda 15
MX - Messico 14
AU - Australia 11
JP - Giappone 9
ZA - Sudafrica 9
FR - Francia 8
ID - Indonesia 8
PL - Polonia 8
BD - Bangladesh 7
UA - Ucraina 7
AR - Argentina 6
BE - Belgio 6
TR - Turchia 5
CO - Colombia 4
PT - Portogallo 4
TW - Taiwan 4
AL - Albania 3
CL - Cile 3
LT - Lituania 3
PY - Paraguay 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EE - Estonia 2
ES - Italia 2
GE - Georgia 2
IE - Irlanda 2
PK - Pakistan 2
TN - Tunisia 2
UZ - Uzbekistan 2
AO - Angola 1
BG - Bulgaria 1
BY - Bielorussia 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
IQ - Iraq 1
JO - Giordania 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MR - Mauritania 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
SN - Senegal 1
SO - Somalia 1
VE - Venezuela 1
YE - Yemen 1
Totale 4.842
Salva come PNG Salva come JPEG
Città #
Hong Kong 294
Singapore 267
Hefei 161
Ashburn 126
Boardman 93
Beijing 90
London 72
Dallas 62
Shanghai 51
Munich 38
Los Angeles 29
Council Bluffs 24
Brno 23
Rome 23
San Francisco 23
Redmond 21
Amsterdam 14
Pune 13
Seattle 12
Guangzhou 11
Mexico City 11
Santa Clara 11
São Paulo 11
Ho Chi Minh City 10
New York 10
Olomouc 10
Turku 10
Toronto 9
Boston 8
Tokyo 8
Washington 8
Brooklyn 7
Hanoi 7
Manchester 7
Helsinki 6
Warsaw 6
Chicago 5
Haiphong 5
Melbourne 5
Atlanta 4
Shenzhen 4
Biên Hòa 3
Campinas 3
Canberra 3
Dhaka 3
Haikou 3
Hangzhou 3
Johannesburg 3
Mol 3
Montreal 3
Paris 3
Stockholm 3
Sydney 3
Taipei 3
The Dalles 3
Tirana 3
Wuhan 3
Ankara 2
Augusta 2
Aversa 2
Chennai 2
Colombo 2
Concord 2
Dublin 2
Florence 2
Genoa 2
Hanover 2
Hasselt 2
Iowa City 2
Limeira 2
Lodz 2
Luoyang 2
Medellín 2
New Delhi 2
North Liberty 2
Oklahoma City 2
Palermo 2
Phoenix 2
Porto 2
Quito 2
Rio de Janeiro 2
San José 2
Tallinn 2
Tashkent 2
Tbilisi 2
Topeka 2
Vilnius 2
West Jordan 2
Xiamen 2
Zhengzhou 2
Alcobaça 1
Alfenas 1
Almaty 1
Amman 1
Apizaco 1
Asunción 1
Bandung 1
Barueri 1
Basseterre 1
Bauru 1
Totale 1.733
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 204
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 186
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 186
Cancer drugs and QT prolongation: weighing risk against benefit 184
Minimal sampling colistin pharmacokinetics in critically ill patients 184
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 178
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 174
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 170
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 170
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 162
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 157
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 154
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 138
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 123
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 106
Anthracyclines 105
Anthracycline Cardiotoxicity 104
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 97
Anthracycline Cardiotoxicity 89
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 85
Cardiotoxicity of antitumor drugs 74
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 69
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 68
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 63
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 52
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 52
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 50
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 47
Pharmacology of Cardio-Oncology 47
What is cardiotoxicity? 45
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 43
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 39
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 39
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 38
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 37
Isavuconazole: case report and pharmacokinetic considerations 37
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 37
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 36
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 35
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 35
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 35
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 34
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 34
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 34
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 33
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 31
Matters of the heart: The case of TNF-alpha targeting drugs 31
The concomitant management of cancer therapy and cardiac therapy 31
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 29
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 29
Molecular determinants of the reduced cardiotoxicity of epirubicin 28
Pharmacological Foundation of Cardio-Oncology 27
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 27
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 27
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 27
Doxorubicin degradation in cardiomyocytes 25
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 25
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 25
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 25
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 24
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 24
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 24
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 24
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 23
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 22
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 22
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 22
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 22
Translating molecular mechanisms into clinical facts 22
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 22
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 22
Humans and Rodents: The Case of hOAT4 and mOat5 21
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 21
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 21
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 21
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 20
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 19
Do you know pixantrone? 18
The reality of pixantrone in real life 17
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 17
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 17
Totale 4.921
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.238
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.238
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022186 0 4 0 0 0 0 1 73 3 0 4 101
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024280 5 32 8 12 32 123 4 16 2 7 4 35
2024/20253.593 74 34 107 13 42 68 37 20 222 238 1.303 1.435
2025/2026816 294 186 127 209 0 0 0 0 0 0 0 0
Totale 4.921